Fox, Julie M <br/><br/>
Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.  [electronic resource] 

 -  Science immunology  02 2019 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>2470-9468 
<br/><br/><label>Standard No.: </label>10.1126/sciimmunol.aav5062  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antibodies, Neutralizing--therapeutic use<br/>Antibodies, Viral--therapeutic use<br/>Arthritis, Experimental--therapy<br/>Chikungunya Fever--virology<br/>Chikungunya virus--immunology<br/>Complement Activation--immunology<br/>Complement C1q--immunology<br/>Disease Models, Animal<br/>Epitopes--immunology<br/>Immunoglobulin Fc Fragments--immunology<br/>Immunologic Factors--therapeutic use<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Monocytes--immunology<br/>Receptor, Interferon alpha-beta--genetics<br/>Receptors, IgG--immunology